RGEN Stock Overview
Develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for RGEN from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Repligen Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$143.81 |
| 52 Week High | US$211.13 |
| 52 Week Low | US$113.50 |
| Beta | 0.96 |
| 1 Month Change | -4.47% |
| 3 Month Change | -1.32% |
| 1 Year Change | -20.02% |
| 3 Year Change | -44.25% |
| 5 Year Change | 53.16% |
| Change since IPO | 1,303.02% |
Recent News & Updates
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
Nov 12Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Nov 08
Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)?
Oct 14Recent updates
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
Nov 12Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Nov 08Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)?
Oct 14Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 28% Above Its Share Price
Sep 08Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Jul 31We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt
Jul 15Repligen: Strong Filtration Growth, Offset By Other Challenges
Jul 13Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge
Jun 14Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?
Jun 10Repligen Stock: Still Quite Overvalued
May 30Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models
May 03Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Apr 30Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Apr 15At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?
Feb 13Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Jan 08Shareholder Returns
| RGEN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -1.3% | -0.5% | -1.1% |
| 1Y | -20.0% | -5.9% | 22.4% |
Return vs Industry: RGEN underperformed the US Life Sciences industry which returned -4.9% over the past year.
Return vs Market: RGEN underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| RGEN volatility | |
|---|---|
| RGEN Average Weekly Movement | 7.1% |
| Life Sciences Industry Average Movement | 9.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RGEN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RGEN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 1,783 | Olivier Loeillot | www.repligen.com |
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.
Repligen Corporation Fundamentals Summary
| RGEN fundamental statistics | |
|---|---|
| Market cap | US$8.15b |
| Earnings (TTM) | -US$8.09m |
| Revenue (TTM) | US$633.51m |
12.7x
P/S Ratio-995.3x
P/E RatioIs RGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGEN income statement (TTM) | |
|---|---|
| Revenue | US$633.51m |
| Cost of Revenue | US$308.99m |
| Gross Profit | US$324.52m |
| Other Expenses | US$332.62m |
| Earnings | -US$8.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 51.23% |
| Net Profit Margin | -1.28% |
| Debt/Equity Ratio | 25.9% |
How did RGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 08:43 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Repligen Corporation is covered by 26 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Hugo Solvet | BNP Paribas Exane |
| Kyle Mikson | Canaccord Genuity |